During the last session, Adaptive Biotechnologies Corp (NASDAQ:ADPT)’s traded shares were 3.12 million, with the beta value of the company hitting 1.71. At the end of the trading day, the stock’s price was $8.22, reflecting an intraday loss of -0.24% or -$0.02. The 52-week high for the ADPT share is $9.01, that puts it down -9.61 from that peak though still a striking 72.26% gain since the share price plummeted to a 52-week low of $2.28. The company’s market capitalization is $1.22B, and the average intraday trading volume over the past 10 days was 2.16 million shares, and the average trade volume was 1.72 million shares over the past three months.
Adaptive Biotechnologies Corp (ADPT) received a consensus recommendation of Hold from analysts. That translates to a mean rating of 1.25. ADPT has a Sell rating from 1 analyst(s) out of 11 analysts who have looked at this stock. 6 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.3.
Adaptive Biotechnologies Corp (NASDAQ:ADPT) trade information
Adaptive Biotechnologies Corp (ADPT) registered a -0.24% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.24% in intraday trading to $8.22, hitting a weekly high. The stock’s 5-day price performance is 6.06%, and it has moved by -1.67% in 30 days. Based on these gigs, the overall price performance for the year is 163.46%. The short interest in Adaptive Biotechnologies Corp (NASDAQ:ADPT) is 9.49 million shares and it means that shorts have 4.82 day(s) to cover.
The consensus price target of analysts on Wall Street is $14, which implies an increase of 41.29% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $5 and $18 respectively. As a result, ADPT is trading at a discount of -118.98% off the target high and 39.17% off the low.
Adaptive Biotechnologies Corp (ADPT) estimates and forecasts
In the rating firms’ projections, revenue will increase 18.85% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 42.13M as predicted by 6 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to 47.3M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 41.87M and 43.19M respectively. In this case, analysts expect current quarter sales to grow by 0.60% and then jump by 9.51% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -1.51%. While earnings are projected to return 14.71% in 2025, the next five years will return 28.67% per annum.
ADPT Dividends
Adaptive Biotechnologies Corp is due to release its next quarterly earnings on 2025-Feb-10. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Adaptive Biotechnologies Corp (NASDAQ:ADPT)’s Major holders
Adaptive Biotechnologies Corp insiders own 2.39% of total outstanding shares while institutional holders control 94.01%, with the float percentage being 96.31%. VIKING GLOBAL INVESTORS LP is the largest shareholder of the company, while 281.0 institutions own stock in it. As of 2024-06-30, the company held over 29.99 million shares (or 20.3466% of all shares), a total value of $108.58 million in shares.
The next largest institutional holding, with 14.0 million shares, is of RUBRIC CAPITAL MANAGEMENT LP’s that is approximately 9.4971% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $50.68 million.
Also, the Mutual Funds coming in first place with the largest holdings of Adaptive Biotechnologies Corp (ADPT) shares are ARK ETF Trust-ARK Genomic Revolution ETF and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund . Data provided on Feb 28, 2025 indicates that ARK ETF Trust-ARK Genomic Revolution ETF owns about 7.9 shares. This amounts to just over 5.32 percent of the company’s overall shares, with a $64.93 million market value. The same data shows that the other fund manager holds slightly less at 4.2, or about 2.83% of the stock, which is worth about $34.51 million.
